First Time Loading...

Adaptimmune Therapeutics PLC
NASDAQ:ADAP

Watchlist Manager
Adaptimmune Therapeutics PLC Logo
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Watchlist
Price: 1.15 USD -1.71% Market Closed
Updated: May 15, 2024
ADAP
/
Income Statement
/
Income from Continuing Operations

Adaptimmune Therapeutics PLC
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Adaptimmune Therapeutics PLC
Income from Continuing Operations Peer Comparison

Comparables:
CNTA
AUTL
BCYC
IMCR
GNS

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Income from Continuing Operations
-$113.9m
CAGR 3-Years
4%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Income from Continuing Operations
-$151.1m
CAGR 3-Years
-142%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Income from Continuing Operations
-$208.4m
CAGR 3-Years
-14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Income from Continuing Operations
-$168.2m
CAGR 3-Years
-44%
CAGR 5-Years
-45%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Income from Continuing Operations
-£55.3m
CAGR 3-Years
9%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Income from Continuing Operations
£30.1m
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
2%

See Also

What is Adaptimmune Therapeutics PLC's Income from Continuing Operations?
Income from Continuing Operations
-113.9m USD

Based on the financial report for Dec 31, 2023, Adaptimmune Therapeutics PLC's Income from Continuing Operations amounts to -113.9m USD.

What is Adaptimmune Therapeutics PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-4%

Over the last year, the Income from Continuing Operations growth was 31%. The average annual Income from Continuing Operations growth rates for Adaptimmune Therapeutics PLC have been 4% over the past three years , -4% over the past five years .

ALPHA SPREAD
Join more than 137,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.